

PRESS RELEASE

Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation

- **InceptionBio is a new €100 million target-size fund focused on biotech company creation and early-stage projects**, with a strong focus on Spain.
- The fund has **already completed a first closing, with participation from CDTI through its SICC Innvierte program**, and aims to support the creation of at least three new biotech companies in 2026.
- The initiative **will be led by Joan Perelló, Managing Partner, and Arturo Urrios, Partner**, further strengthening Ysios' ability to identify, build and develop projects from the earliest stages.

SAN SEBASTIÁN/BARCELONA, March 27, 2026 – [Ysios Capital](#), a leading European venture capital firm specialized in life sciences, today announced the launch of **InceptionBio, a new fund with a target size of €100 million** focused on biotech company creation and early-stage project development.

The fund has already completed a **first closing, with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte program**, which supports investment in high-potential innovative companies.

InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. **The fund will primarily invest in technology transfer opportunities and early-stage companies**, enabling Ysios to work closely with universities, research centers and scientific entrepreneurs to accelerate the translation of scientific discoveries into new therapies that can deliver meaningful impact for patients.

CDTI-Innvierte's backing reinforces public-private collaboration in a strategic area for the Spanish biotech ecosystem and will help accelerate technology transfer, foster the creation of high-growth innovation-led companies, and strengthen the competitiveness of Spain's R&D system.

The initiative will be led by Joan Perelló, Managing Partner, and Arturo Urrios, Partner, who bring extensive experience in biomedical innovation, venture capital and company creation. **This new strategy complements Ysios Capital's existing investment approach and expands its ability to engage from the earliest stages.**

"Spain has world-class science and a unique opportunity to translate that science into globally impactful biotech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients," said **Joan Perelló, Managing Partner at Ysios Capital**.

InceptionBio's strategy combines building new companies around scientific assets emerging from universities and research centers with identifying and attracting international assets that can be developed in Spain. **Through this strategy, Ysios aims to strengthen the Spanish biotech ecosystem and help position Spain as a leading biotech hub.**

The fund already has a pipeline of investment opportunities in advanced review and **aims to support the creation of at least three new biotech companies in 2026.**

"We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them. InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain," added **Arturo Urrios, Partner at Ysios Capital**.

With the launch of InceptionBio, Ysios is further expanding its ability to support biomedical innovation across the value chain, from company creation through later-stage development, complementing its current investment strategy and its role as investment advisor to Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management. The Ysios team brings extensive experience in innovation, entrepreneurship and company building in life sciences, having contributed to the creation and growth of multiple biotech companies over the past two decades.

A leading firm with a strong track record in biotech investing

Throughout its history, Ysios Capital has invested in more than 40 biotech companies and has completed six NASDAQ exits and ten M&A transactions, establishing itself as a leading investor in the European life sciences sector.

The firm has participated in some of the most significant transactions in the Spanish biotech ecosystem, including investments in companies such as Tigenix/Cellerix, Sanifit, STAT-Diagnostica, Ona Therapeutics, SpliceBio and Minoryx Therapeutics. Ysios has also played a key role in landmark transactions such as the acquisition of Tigenix by Takeda (approximately €450 million), the sale of STAT-Diagnostica to Qiagen (€172 million), and the acquisition of Sanifit by Vifor Pharma (€375 million)

Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies developing life-changing treatments for patients, with a focus on areas of high unmet medical need.

Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs, generating financial returns and a positive impact on society.

Founded in 2008, Ysios Capital manages over €400 million in assets through its three venture capital funds and also acts as investment advisor to Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management (<https://andbank.es/boutiquehub/ysios/>). For more information, please visit www.ysioscapital.com.

Para más información

Miriam Cortés, Ysios Capital

T 93 517 3545

mcortes@ysioscapital.com

www.ysioscapital.com